Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Parapemikir Jurnal Ilmiah Farmasi
Erna Prasetya Ningrum
Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang
Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology Physics

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
PENGGUNAAN OBAT DIABETES MELLITUS PADA PASIEN RAWAT JALAN YANG MENJALANKAN HEMODIALISA Erna Prasetya Ningrum
Parapemikir : Jurnal Ilmiah Farmasi Vol 11, No 2 (2022): Parapemikir : Jurnal Ilmiah Farmasi
Publisher : Pusat Penelitian dan Pengabdian Masyarakat Politeknik Harapan Bersama

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30591/pjif.v11i2.3236

Abstract

Kidney dysfunction causes diseases including chronic kidney failure (CKD), where the state of decreased kidney function in the body is quite severe. CKD is permanent or irreversible damage, the damage that occurs cannot be repaired or returned to normal [12]. Based on the cause, kidney failure is caused by several diseases, including diabetes mellitus by 44% [12]. One of the main causes of chronic kidney failure in people with diabetes mellitus, the existence of a hyperglycemic state where several co-morbidities appear including disorders of the retina of the eye, cardiovascular, neuro [10]. The purpose of the study was to determine the number of kidney failure patients who underwent hemodialysis who received antihyperglycemic drugs, classes, and doses. The research method, the data collection was done retrospectively, the sample was taken by purposive sampling. The results showed that based on the sex of men as much as 31.58% and women by 68.42%, ages 46-55 years as many as 84.21%, single drug use by 81%, use of glycuidon dose of 30 mg by 33%. Conclusion of the data obtained The use of the drug glycuidone is relatively safe to use for patients with diabetes mellitus with kidney complications who are undergoing hemodialysis. The use of insulin in DM-complicated CKD patients will affect the state of blood insulin
Co-Authors